Floria Lizarraga

Floria Lizarraga

Auto-generated profile, based on publicly available information

Floria Lizarraga

Instituto Nacional de Medicina Genómica (INMEGEN)

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2015 in Experimental Cell Research
Verified
Journal Article
Closed access
LMLuz María Mejia-Cristobal
Luz María Mejia-Cristobal
ERErika Reus
Erika Reus
FLFloria Lizarraga
Floria Lizarraga
EEEspinosa Espinosa
Espinosa Espinosa
GCGisela Ceballos-Cancino
Gisela Ceballos-Cancino
JMJorge Melendez-Zajgla
Jorge Melendez-Zajgla

9 April 2021 in Cancer Biomarkers
Verified
Journal Article
Closed access
PDF file
JLJose Manuel Sanchez Lopez
Jose Manuel Sanchez Lopez
EMEdna Ayerim Mandujano-Tinoco
Edna Ayerim Mandujano-Tinoco
AGAlfredo Garcia-Venzor
Alfredo Garcia-Venzor
LLLaura Fatima Lozada-Rodriguez
Laura Fatima Lozada-Rodriguez
CZCECILIA ZAMPEDRI
CECILIA ZAMPEDRI
FLFloria Lizarraga
Floria Lizarraga
BACKGROUND: Long-non-coding RNAs, a class of transcripts with lengths > 200 nt, play key roles in tumour progression. Previous reports revealed that LINC00052 (long intergenic non-coding RNA 00052) was strongly downregulated during breast cancer multicellular spheroids formation and suggested a role in cell migration and oxidative metabolism. OBJECTIVE: To examine the function of LINC00052 in MCF-7 breast cancer cells. METHODS: Loss-of-function studies were performed to evaluate LINC00052 role on MCF-7 breast cancer cells. Microarray expression assays were performed to determine genes and cellular functions modified after LINC00052 knockdown. Next, the impact of LINC00052 depletion on MCF-7 cell respiration and migration was evaluated. RESULTS: 1,081 genes were differentially expressed upon LINC00052 inhibition. Gene set enrichment analysis, Gene Ontology and Key Pathway Advisor analysis showed that signalling networks related to cell migration and oxidative phosphorylation were enriched. However, whereas LINC00052 knockdown in MCF-7 cells revealed marginal difference in oxygen consumption rates when compared with control cells, LINC00052 inhibition enhanced cell migration in vitro and in vivo, as observed using a Zebrafish embryo xenotransplant model. CONCLUSION: Our data show that LINC00052 modulates MCF-7 cell migration. Genome-wide microarray experiments suggest that cancer cell migration is affected by LINC00052 through cytoskeleton modulation and Notch/β-catenin/NF-κB signalling pathways.

Verified
Journal Article
Open access
PDF file
ARAraceli Ruiz
Araceli Ruiz
AGAlfredo Garcia-Venzor
Alfredo Garcia-Venzor
GCGisela Ceballos-Cancino
Gisela Ceballos-Cancino
JLJose Manuel Sanchez Lopez
Jose Manuel Sanchez Lopez
KVKARLA VAZQUEZ-SANTILLAN
KARLA VAZQUEZ-SANTILLAN
VMVilma Maldonado
Vilma Maldonado
Breast cancer is a leading cause of cancer-related deaths among women. Cisplatin is used for treatment, but the development of resistance in cancer cells is a significant concern. This study aimed to investigate changes in the transcriptomes of cisplatin-resistant MCF7 cells. We conducted RNA sequencing of cisplatin-resistant MCF7 cells, followed by differential expression analysis and bioinformatic investigations to identify changes in gene expression and modified signal transduction pathways. We examined the size and quantity of extracellular vesicles. A total of 724 genes exhibited differential expression, predominantly consisting of protein-coding RNAs. Notably, two long non-coding RNAs (lncRNAs), NEAT1 and MALAT, were found to be dysregulated. Bioinformatic analysis unveiled dysregulation in processes related to DNA synthesis and repair, cell cycle regulation, immune response, and cellular communication. Additionally, modifications were observed in events associated with extracellular vesicles. Conditioned media from resistant cells conferred resistance to wild-type cells in vitro. Furthermore, there was an increase in the number of vesicles in cisplatin-resistant cells. Cisplatin-resistant MCF7 cells displayed differential RNA expression, including the dysregulation of NEAT1 and MALAT long non-coding RNAs. Key processes related to DNA and extracellular vesicles were found to be altered. The increased number of extracellular vesicles in resistant cells may contribute to acquired resistance in wild-type cells.

4 June 2024 in RNA Biology
Verified
Journal Article
Open access
JSJose Manuel Sanchez-Lopez
Jose Manuel Sanchez-Lopez
MJMiguel Angel Juarez-Mancera
Miguel Angel Juarez-Mancera
BBBenjamin Bustamante
Benjamin Bustamante
ARAraceli Ruiz-Silvestre
Araceli Ruiz-Silvestre
MEMagali Espinosa
Magali Espinosa
FLFloria Lizarraga
Floria Lizarraga
LncRNA is a group of transcripts with a length exceeding 200 nucleotides that contribute to tumour development. Our research group found that LINC00052 expression was repressed during the formation of breast cancer (BC) multicellular spheroids. Intriguingly, LINC00052 precise role in BC remains uncertain. We explored LINC00052 expression in BC patients` RNA samples (TCGA) in silico, as well as in an in-house patient cohort, and inferred its cellular and molecular mechanisms. In vitro studies evaluated LINC00052 relevance in BC cells viability, cell cycle and DNA damage. Results. Bioinformatic RNAseq analysis of BC patients showed that LINC00052 is overexpressed in samples from all BC molecular subtypes. A similar LINC00052 expression pattern was observed in an in-house patient cohort. In addition, higher LINC00052 levels are related to better BC patient´s overall survival. Remarkably, MCF-7 and ZR-75-1 cells treated with estradiol showed increased LINC00052 expression compared to control, while these changes were not observed in MDA-MB-231 cells. In parallel, bioinformatic analyses indicated that LINC00052 influences DNA damage and cell cycle. MCF-7 cells with low LINC00052 levels exhibited increased cellular protection against DNA damage and diminished growth capacity. Furthermore, in cisplatin-resistant MCF-7 cells, LINC00052 expression was downregulated. Conclusion. This work shows that LINC00052 expression is associated with better BC patient survival. Remarkably, LINC00052 expression can be regulated by Estradiol. Additionally, assays suggest that LINC00052 could modulate MCF-7 cells growth and DNA damage repair. Overall, this study highlights the need for further research to unravel LINC00052 molecular mechanisms and potential clinical applications in BC.